Background
ADCs and AOCs have achieved significant successes in oncology and are now expanding their applications to non-cancer areas such as autoimmune diseases, inflammatory conditions, and infectious diseases, thanks to their target specificity and potent efficacy. However, the manufacturing of these advanced conjugated pharmaceuticals is considerably more complex than that of traditional small molecule drugs or simpler biologics. Manufacturing challenges directly impact the stability of global supply chains, cost-efficiency, and adherence to regulatory requirements. Therefore, considering manufacturability from the earliest stages of development is indispensable for successful product commercialization. The industry’s push for these advanced modalities necessitates a corresponding evolution in manufacturing science to ensure their broad clinical utility.
Key Findings
In the evolving landscape of Antibody-Drug Conjugate (ADC) and Oligonucleotide-Drug Conjugate (AOC) development, it is critical to identify CMC (Chemistry, Manufacturing, and Controls) risks early and establish robust conjugation strategies. This proactive approach is essential for bridging the gap between innovative early-stage research and the clinical and commercial realities of large-scale manufacturing, especially as these modalities expand rapidly beyond oncology into other therapeutic areas.
Technical Details
- ADCs and AOCs represent next-generation therapeutics that employ an antibody or oligonucleotide as a carrier to specifically deliver therapeutic agents to target cells or tissues.
- Manufacturing these conjugates demands highly specialized expertise and stringent quality control, involving complex chemical linkages between large biomolecules (antibodies or oligonucleotides) and small molecule drugs.
- Early identification of CMC risks is crucial to prevent costly failures and delays in late-stage development. This includes initial assessments of conjugation efficiency, stability, purity, and reproducibility during scale-up.
- A “robust conjugation strategy” refers to the technologies that ensure the conjugate maintains stability both in vitro and in vivo, preventing premature drug release before reaching target cells. This maximizes therapeutic efficacy while minimizing off-target toxicity.
- An integrated “Quality by Design (QbD)” approach, aligning molecular design, CMC strategy, and process control from the earliest development stages, is directly linked to ensuring consistent supply and accelerating time-to-market.
Strategic Implications and Outlook
The adoption of early CMC risk management and robust conjugation strategies will be indispensable for ensuring the clinical and commercial scalability of ADCs and AOCs. This approach is expected to enhance pipeline efficiency, accelerating the delivery of innovative therapies to patients. Furthermore, advancements in manufacturing process standardization and automation could lead to cost reductions for these often-expensive therapeutics, ultimately improving healthcare access. Across the industry, a cohesive development strategy that closely integrates molecular design, manufacturing processes, and quality control will be key to the success of next-generation conjugated pharmaceuticals, driving the future of precision drug delivery.
Source: #
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments